SCHEMBL14617754

SCHEMBL14617754

CCOC(=O)[C@H](Cc1ccc(OCc2ccccc2)c(OCc2ccccc2)c1)NC(=O)NCc1ccc(C)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 3/20 0.64
▸ L3MBTL1 Q9Y468 1/20 0.64
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ KLKB1 P03952 1/20 0.47
▸ PPID Q08752 2/20 0.47
▸ POLB P06746 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ THRB P10828 1/20 0.46
▸ LCK P06239 1/20 0.46
▸ PPARA Q07869 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ ANPEP P15144 1/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ TP53 P04637 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2040860 0.92 PPID (0.58) ATML3MBTL1SMN1; SMN2KLKB1PPID
SCHEMBL12643651 0.92 PPID (0.58) ATML3MBTL1SMN1; SMN2KLKB1PPID
SCHEMBL15832199 0.89 ATM (0.57) ATML3MBTL1SMN1; SMN2KLKB1PPID
SCHEMBL14617704 0.88 ATM (0.64) ATML3MBTL1SMN1; SMN2KLKB1PPID
SCHEMBL12643655 0.86 MAPT (0.51) ATML3MBTL1KLKB1POLBMAPT
SCHEMBL14576371 0.86 MAPT (0.51) ATML3MBTL1KLKB1POLBMAPT
SCHEMBL8409365 0.84 TACR1 (0.58) ATMSMN1; SMN2POLBMAPTTHRB
SCHEMBL16270324 0.83 ATM (0.65) ATML3MBTL1SMN1; SMN2KLKB1PPID
SCHEMBL14617757 0.83 ATM (0.65) ATML3MBTL1SMN1; SMN2KLKB1POLB
SCHEMBL15942658 0.82 POLB (0.51) ATML3MBTL1SMN1; SMN2POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8901295-B2 Inhibitors of cyclophilins and uses thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-12-02 — — US disclosed
US-8802666-B2 Inhibitors of cyclophilins and uses thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-08-12 — — US disclosed
US-20130018044-A1 NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2013-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018044-A1 NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF FKBP3, FKBP4, FKBP5 ATM 4698/4885L3MBTL1 3342/4885SMN1; SMN2 2177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback